Rezolute will host the conference call presentation and data discussion on Sunday, May 1 at 2:30 p.m. ET
REDWOOD CITY, Calif., April 26, 2022 (GLOBE NEWSWIRE) — Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to disrupt current treatment paradigms for devastating metabolic diseases, today announced a late-breaking oral presentation of key data from the RIZE study. phase 2b study of RZ358 in congenital hyperinsulinism (HI) at the upcoming 2022 Pediatric Endocrine Society Annual Meeting on May 1, 2022.
On behalf of the company and study co-authors, Dr. Paul Thornton, pediatric endocrinologist and head of the Hyperinsulinism Center at Cook Children’s Hospital, is to present the results of the Phase 2b, multicenter, global study to repeat doses of RZ358 in patients with congenital IH. The RIZE study was designed to evaluate the safety and tolerability, pharmacokinetics, and glycemic efficacy of RZ358 administered every other month for 8 weeks in patients with congenital IH whose hypoglycemia was not sufficiently controlled by existing standard care treatments.
Presentation title: RZ358 in congenital hyperinsulinism: results of a global multicenter phase 2b study (RIZE)
Presenter: Paul Thornton, MD
Session date and time: Sunday, May 1, 2022, from 12:00 p.m. to 1:30 p.m. ET
Session title: Clinic – Endocrinology
Abstract #: 6071
Presentation on demand: Available from Monday, May 2, 2022 at 11:30 a.m. ET
Conference Call and Webcast Information
Rezolute management will host a conference call at 2:30 p.m. ET on Sunday, May 1, 2022. Analysts and investors are invited to participate in the conference call by dialing (855) 645-1306 from the United States and Canada or (442) 268-1087 internationally and using conference ID 6063004. The live webcast can be accessed on the investor page of Rezolute’s website at ir.rezolutebio.com. A replay of the webcast will be available on the Rezolute website approximately two hours after the event ends and will be archived for up to 90 days.
About Rezolute, Inc.
Rezolute strives to disrupt current treatment paradigms by developing transformative therapies for devastating rare and chronic metabolic diseases. Its new therapies have the potential to significantly improve outcomes and reduce the treatment burden for patients, the treating physician and the healthcare system. The voices of patients, clinicians and advocates are integrated into the company’s drug development process, enabling Rezolute to boldly treat a range of serious conditions. Rezolute is unwavering in its mission to create a profound, positive and lasting impact on the lives of patients. The Company’s lead clinical asset, RZ358, is in late-stage development for the treatment of congenital hyperinsulinism, a rare pediatric endocrine disorder. Rezolute is also developing RZ402, an orally available plasma kallikrein inhibitor, for the treatment of diabetic macular edema. For more information, visit www.rezolutebio.com or follow us on Twitter.
This release, like many written and oral communications presented by Rezolute, Inc. and our authorized officers, may contain certain forward-looking statements regarding our performance and forward-looking strategies within the meaning of Section 27A of the Securities Act and the Section 21E of the Securities Exchange. Act of 1934, as amended. We intend that these forward-looking statements be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and include this statement for the purposes of such safe harbor provisions. Forward-looking statements, which are based on certain assumptions and describe the future plans, strategies and expectations of the Company, are generally identified by the use of words such as “anticipate”, “believe”, “estimate”, “expect to”, “intend”, “plan”, “project”, “seek”, “strive”, “try”, or future or conditional verbs such as “could”, “can”, “should”, “will”, “would”, or similar expressions. Our ability to predict the actual results or effects of our plans or strategies is inherently uncertain. Accordingly, actual results may differ materially from anticipated results. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Except as required by applicable law or regulation, Rezolute undertakes no obligation to update these forward-looking statements. to reflect events or circumstances events that occur after the date on which such statements were made.
Kimberly Minarovich/Carrie McKim
Canal Communications, Inc.